Artur Menegaz de Almeida

Artur Menegaz de Almeida

Auto-generated profile, based on publicly available information

Artur Menegaz de Almeida

Federal University of Mato Grosso, Sinop, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
AAArtur Menegaz de Almeida
Artur Menegaz de Almeida
FMFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
MSMaria Eduarda Cavalcanti Souza
Maria Eduarda Cavalcanti Souza
JCJorge Henrique Cavalcanti Orestes Cardoso
Jorge Henrique Cavalcanti Orestes Cardoso
FTFernanda Tamashiro
Fernanda Tamashiro
FKFrancinny Alves Kelly
Francinny Alves Kelly
Importance: Seasonal humor disorders are prone to have a link with daylight exposure. However, the effect of external light on nonseasonal disorders remains unclear. Evidence is lacking for the validity of bright light therapy (BLT) as an adjunctive treatment for these patients.Objective: To assess BLT effectiveness as an adjunctive treatment for nonseasonal depressive disorders.Data Sources: In March 2024, a comprehensive search was performed of publications in the MEDLINE, Embase, and Cochrane databases for randomized clinical trials (RCTs) evaluating BLT effects in patients with nonseasonal depression.Study Selection: RCTs published since 2000 were eligible. Comparisons between BLT and dim red light or antidepressant monotherapy alone were considered for inclusion.Data Extraction and Synthesis: Using the systematic review approach on RCTs published from January 1, 2000, through March 25, 2024, differences between patients treated with and without BLT were estimated using the Mantel-Haenszel method; heterogeneity was assessed using I2 statistics.Main Outcomes and Measures: Remission of symptoms, response to treatment rates, and depression scales were assessed.Results: In this systematic review and meta-analysis of 11 unique trials with data from 858 patients (649 female [75.6%]), statistically significant better remission and response rates were found in the BLT group (remission: 40.7% vs 23.5%; odds ratio [OR], 2.42; 95% CI, 1.50-3.91; P <.001; I2 = 21%; response: 60.4% vs 38.6%; OR, 2.34; 95% CI, 1.46-3.75; P <.001; I2 = 41%). With BLT, subgroup analysis based on follow-up times also showed better remission (<4 weeks: 27.4% vs 9.2%; OR, 3.59; 95% CI, 1.45-8.88; P = .005; I2 = 0% and >4 weeks: 46.6% vs 29.1%; OR, 2.18; 95% CI, 1.19-4.00; P = .01; I2 = 47%) and response (<4 weeks: 55.6% vs 27.4%; OR, 3.65; 95% CI, 1.81-7.33; P <.001; I2 = 35% and >4 weeks: 63.0% vs 44.9%; OR, 1.79; 95% CI, 1.01-3.17; P = .04; I2 = 32%) rates.Conclusions and Relevance: Results of this systematic review and meta-analysis reveal that BLT was an effective adjunctive treatment for nonseasonal depressive disorders. Additionally, results suggest that BLT may improve the response time to the initial treatment.

2 January 2025 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
AAArtur Menegaz de Almeida
Artur Menegaz de Almeida
POPaloma Oliveira
Paloma Oliveira
LLLucca Lopes
Lucca Lopes
MLMarianna Leite
Marianna Leite
VMVictória Morbach
Victória Morbach
APAlexandra Prevedello
Alexandra Prevedello
OBJECTIVE: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women. DATA SOURCES: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.gov. The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptoms in menopausal women were included. TABULATION, INTEGRATION, AND RESULTS: We extracted the number of patients, mean age, body mass index (BMI), and number of patients who underwent oophorectomy. Data were examined with the Mantel–Haenszel method and 95% CIs. Heterogeneity was assessed with I 2 statistics. R 4.3.2 was used for statistical analysis. Seven RCTs with 4,087 patients were included in the analysis. Fezolinetant and elinzanetant were associated with diminished vasomotor symptom frequency: fezolinetant 30 mg (mean difference 2.16, 95% CI, 1.54–2.79, I 2=0%), fezolinetant 45 mg (mean difference 2.54, 95% CI, 1.86–3.21, I 2=0%), and elinzanetant 120 mg (mean difference 2.99, 95% CI, 1.74–4.23, I 2=0%). Both drugs also showed a decrease in vasomotor symptom severity: fezolinetant 30 mg (mean difference 0.20, 95% CI, 0.09–0.33, I 2=0%), fezolinetant 45 mg (mean difference 0.24, 95% CI, 0.13–0.34, I 2=0%), and elinzanetant 120 mg (mean difference 0.36, 95% CI, 0.26–0.46, I 2=0%). Elinzanetant 120 mg showed a significant improvement in sleep quality (mean difference 4.65, 95% CI, 3.73–5.56, I 2=0%). Elinzanetant 120 mg was associated with the occurrence of drug-related adverse events (11.70% vs 20.75%, risk ratio [RR] 0.57, 95% CI, 0.39–0.82, I 2=19%) and headache (2.54% vs 8.0%, RR 0.32, 95% CI, 0.16–0.64, I 2=0%). CONCLUSION: In this meta-analysis, consistent results suggest that fezolinetant and elinzanetant are associated with beneficial outcomes in menopausal women with vasomotor symptoms. Elinzanetant provided a larger effect size in vasomotor symptom frequency and severity reduction and greatly improved sleep quality compared with fezolinetant. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023469952.

29 November 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
EPEric Pasqualotto
Eric Pasqualotto
LLLucca Moreira Lopes
Lucca Moreira Lopes
MSMaria Eduarda Cavalcanti Souza
Maria Eduarda Cavalcanti Souza
Anna Luíza Soares de Oliveira RodriguesAnna Luíza Soares de Oliveira Rodrigues
Anna Luíza Soares de Oliveira Rodrigues
NSNey Santos
Ney Santos
Background: Paclitaxel and carboplatin is the standard chemotherapy for the treatment of advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors to chemotherapy is still unclear. Method: We searched PubMed, Scopus, Cochrane, and Web of Science databases for randomized controlled trials that investigated PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs). We used DerSimonian and Laird random-effect models for all endpoints. Heterogeneity was assessed using I2 statistics. R, version 4.2.3, was used for statistical analyses. Results: A total of three studies and 1,431 patients were included. Compared with carboplatin plus paclitaxel-based chemotherapy, progression-free survival (PFS) rate (HR 0.32; 95% CI 0.23–0.44; p < 0.001) and overall survival (OS) at 30 months (RR 3.13; 95% CI 1.26–7.78; p = 0.01) were significant in favor of the PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel group in the mismatch repair–deficient subgroup. However, there were no significant differences in the mismatch repair–proficient subgroup for PFS (HR 0.74; 95% CI 0.50–1.08; p = 0.117) or OS at 30 months (RR 2.24; 95% CI 0.79–6.39; p = 0.13). Conclusion: Immunotherapy plus carboplatin-paclitaxel increased significantly PFS and OS among patients with advanced or recurrent endometrial cancer, with a significant benefit in the mismatch repair–deficient and high microsatellite instability population.

26 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EPEric Pasqualotto
Eric Pasqualotto
Francisco Cezar Aquino de MoraesFrancisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
MSMaria Eduarda Cavalcanti Souza
Maria Eduarda Cavalcanti Souza
Anna Luíza Soares de Oliveira RodriguesAnna Luíza Soares de Oliveira Rodrigues
Anna Luíza Soares de Oliveira Rodrigues
NSNey Santos
Ney Santos
Background: The benefit of adding programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors to the treatment of early-stage non-small cell lung cancer (NSCLC), both neoadjuvant therapy (NAT) and adjuvant therapy (AT), is not yet fully elucidated. Methods: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCT) that investigated PD-1/PD-L1 inhibitors plus chemotherapy for resectable stage NSCLC. We computed hazard ratios (HRs) or odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs). Results: A total of seven RCTs comprising 3915 patients with resectable stage NSCLC were randomized to chemotherapy with or without PD-1/PD-L1 inhibitors as NAT or AT. As NAT, the PD-1/PD-L1 inhibitors plus chemotherapy group demonstrated significantly improved overall survival (HR 0.66; 95% CI 0.51–0.86) and event-free survival (HR 0.53; 95% CI 0.43–0.67) compared with the chemotherapy alone group. There was a significant increase in favor of the PD-1/PD-L1 inhibitors plus chemotherapy group for major pathological response (OR 6.40; 95% CI 3.86–10.61) and pathological complete response (OR 8.82; 95% CI 4.51–17.26). Meanwhile, as AT, disease-free survival was significant in favor of the PD-1/PD-L1 inhibitors plus chemotherapy group (HR 0.78; 95% CI 0.69–0.90). Conclusions: In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of PD-1/PD-L1 inhibitors alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with resectable stages of NSCLC. Moreover, our analyses support that neoadjuvant administration with these agents should be encouraged, in light of the fact that it was associated with an increased survival and pathological response, at the expense of a manageable safety profile.

28 November 2024 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
AAArtur Menegaz de Almeida
Artur Menegaz de Almeida
FTFernanda Moraes Tamashiro
Fernanda Moraes Tamashiro
MSMaria Eduarda Cavalcanti Souza
Maria Eduarda Cavalcanti Souza
ISIasmin Isabelli Luiz Silvério
Iasmin Isabelli Luiz Silvério
CMCelso de Almeida Souza Miranda
Celso de Almeida Souza Miranda
FKFrancinny Alves Kelly
Francinny Alves Kelly

29 March 2024 in Neurosurgery
Verified
Journal Article
Closed access
AAArtur Menegaz de Almeida
Artur Menegaz de Almeida
PVPatrícia Viana
Patrícia Viana
GMGabriel Marinheiro
Gabriel Marinheiro
JRJessica Hoffmann Relvas
Jessica Hoffmann Relvas
LLLucca Moreira Lopes
Lucca Moreira Lopes
KMKhalid Medani
Khalid Medani
BACKGROUND AND OBJECTIVES: The preferred osmotic agent used for brain relaxation during craniotomies remains unclear, either mannitol (MAN) or hypertonic saline (HTS). Hence, we sought to compare these solutions in this population. METHODS: MEDLINE, Embase, and Cochrane databases were systematically searched until August 02, 2023. Data were examined using the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed using I 2 statistics. Meta-regression analysis was conducted to evaluate a possible link between Brain Relaxation Score and tumor volume. R, version 4.2.3, was used for statistical analysis. RESULTS: A total of 16 randomized controlled trials and 1031 patients were included, of whom 631 (61%) underwent surgery for supratentorial tumor resection. Compared with MAN, HTS achieved better rates of brain relaxation (80% vs 71%; odds ratio [OR] 1.68; 95% CI 1.22-2.33; P = .001; I 2 = 0%), which was also demonstrated in the subgroup analysis of patients with supratentorial brain tumor (78% vs 65%; OR 2.02; 95% CI 1.36-2.99; P = .0005; I 2 = 0%); a minor number of patients requiring a second dose of osmotic agent (14% vs 28%; OR 0.43; 95% CI 0.27-0.69; P = .0003; I 2 = 0%); a lower fluid intake (mean difference −475.9341 mL; 95% CI −818.8952 to −132.9730; P = .007; I 2 = 88%); and lower urine output (mean difference −462.0941 mL; 95% CI −585.3020 to −338.8862; P = <.001; I 2 = 96%). Hospital length of stay and focal neurological deficits did not reach a statistically significant difference between groups. CONCLUSION: In this updated meta-analysis, consistent results suggest that HTS is associated with more beneficial outcomes than MAN in patients undergoing craniotomy.